Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arterra Bioscience SpA has the GF Score of 77, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Arterra Bioscience SpA
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Arterra Bioscience SpA GF Score Related Terms
MIL:ARBS vs VRTX, REGN, ALNY: GF Score Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's GF Score distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's GF Score falls into.
Arterra Bioscience SpA (MIL:ARBS) has a GF Score of 77 as of Jul. 20, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Arterra Bioscience SpA and its competitors. This is 71% above median its historical median of 45.00. Over the past decade, Arterra Bioscience SpA's GF Score has ranged from 17.00 to 93.00.
Is Arterra Bioscience SpA's GF Score too high?
Arterra Bioscience SpA's current GF Score of 77 is 71% above median its 10-year median of 45.00. Over the past 10 years, this metric has ranged from a low of 17.00 to a high of 93.00. Overall, Arterra Bioscience SpA has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's GF Score compare to VRTX and REGN?
Arterra Bioscience SpA's GF Score of 77 can be compared against companies in the Biotechnology industry. Historically, Arterra Bioscience SpA's own GF Score has ranged from 17.00 to 93.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Arterra Bioscience SpA and its competitors. Arterra Bioscience SpA's current GF Score is 77, which is 71% above median its own 10-year median of 45.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.91, compared to a current price of €3.04 — trading 4.5% above its estimated fair value. The current GF Score is 77, which is 71% above median its 10-year median of 45.00. Arterra Bioscience SpA's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current GF Score is 77 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.04 is trading 4.5% above its estimated GF Value™ of €2.91.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
GF Score: 77 (71% above median its 10-year median of 45.00)
GF Value™: €2.91 vs. price of €3.04 (4.5% above fair value)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
77GF Score
Get the complete analysis for MIL:ARBS
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
